Phase II Trial of Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Dasatinib (Primary) ; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 06 Jan 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Dec 2012 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 03 Dec 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.